Back to search

Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.

Charles G. Drake, David F. McDermott, Mario Sznol, Toni K. Choueiri, Harriet M. Kluger
DOI: 10.1200/jco.2013.31.15_suppl.4514
Journal of Clinical Oncology

Data up to Jan 2025

Published2013
Citations56
References0
Fields
MedicineInternal medicineOncologyEnvironmental health

Total Citations Per Year

Abstract

References (0)

No references found

Cited By (0)

Loading...
Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558;… (2013) – Journal of Clinical Oncology | Metascience Observatory Explorer